Compare Stocks: RCDTF, UCBJY, TEVA, and OTSKY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OTSKY Otsuka	$39.05 +1.0%	$34.70	$25.30 ▼ $40.92	$41.52B	-0.04	34,902 shs	39,068 shs
RCDTF Recordati Industria Chimica E Farmaceutica	$58.00	$58.36	$55.88 ▼ $60.00	$11.97B	0.25	1 shs	N/A
TEVA Teva Pharmaceutical Industries	$36.52 -0.6%	$33.47	$17.33 ▼ $37.39	$42.81B	0.86	5.78 million shs	7.61 million shs
UCBJY UCB	$126.17 -1.3%	$140.70	$111.72 ▼ $168.76	$48.31B	0.47	46,895 shs	28,971 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OTSKY Otsuka	-2.31%	+3.18%	+14.10%	+6.79%	+43.76%
RCDTF Recordati Industria Chimica E Farmaceutica	0.00%	0.00%	0.00%	+3.79%	-11.37%
TEVA Teva Pharmaceutical Industries	+1.00%	+6.06%	+14.58%	+4.29%	+122.20%
UCBJY UCB	-2.04%	-3.34%	-4.70%	-8.32%	+16.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OTSKY Otsuka	$39.05 +1.0%	$34.70	$25.30 ▼ $40.92	$41.52B	-0.04	34,902 shs	39,068 shs
RCDTF Recordati Industria Chimica E Farmaceutica	$58.00	$58.36	$55.88 ▼ $60.00	$11.97B	0.25	1 shs	N/A
TEVA Teva Pharmaceutical Industries	$36.52 -0.6%	$33.47	$17.33 ▼ $37.39	$42.81B	0.86	5.78 million shs	7.61 million shs
UCBJY UCB	$126.17 -1.3%	$140.70	$111.72 ▼ $168.76	$48.31B	0.47	46,895 shs	28,971 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OTSKY Otsuka	-2.31%	+3.18%	+14.10%	+6.79%	+43.76%
RCDTF Recordati Industria Chimica E Farmaceutica	0.00%	0.00%	0.00%	+3.79%	-11.37%
TEVA Teva Pharmaceutical Industries	+1.00%	+6.06%	+14.58%	+4.29%	+122.20%
UCBJY UCB	-2.04%	-3.34%	-4.70%	-8.32%	+16.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OTSKY Otsuka	2.00	Hold	N/A	N/A
RCDTF Recordati Industria Chimica E Farmaceutica	3.00	Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.90	Moderate Buy	$42.22	15.62% Upside
UCBJY UCB	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest RCDTF, UCBJY, TEVA, and OTSKY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	TEVA Teva Pharmaceutical Industries	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $42.00
8/4/2026	UCBJY UCB	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	UCBJY UCB	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
7/31/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
7/28/2026	TEVA Teva Pharmaceutical Industries	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$42.00 ➝ $44.00
7/17/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	UCBJY UCB	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
6/22/2026	UCBJY UCB	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Sell
6/15/2026	UCBJY UCB	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/11/2026	UCBJY UCB	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/13/2026	UCBJY UCB	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OTSKY Otsuka	$16.51B	2.54	$3.02 per share	12.95	$19.33 per share	2.02
RCDTF Recordati Industria Chimica E Farmaceutica	$2.96B	4.04	N/A	N/A	N/A	∞
TEVA Teva Pharmaceutical Industries	$17.26B	2.47	$3.71 per share	9.85	$6.66 per share	5.48
UCBJY UCB	$8.76B	5.45	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OTSKY Otsuka	$2.43B	$2.49	15.68	17.75	7.31	15.50%	12.93%	9.55%	10/30/2026 (Estimated)
RCDTF Recordati Industria Chimica E Farmaceutica	$501.92M	$2.80	20.68	N/A	N/A	18.38%	34.46%	12.82%	N/A
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	60.86	12.05	3.93	4.08%	32.64%	6.34%	N/A
UCBJY UCB	$1.76B	N/A	N/A	16.01	1.04	N/A	N/A	N/A	N/A

Latest RCDTF, UCBJY, TEVA, and OTSKY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2026	Q2 2026	OTSKY Otsuka	$0.5060	$0.70	+$0.1940	$0.70	$3.95 billion	$4.41 billion
7/29/2026	Q2 2026	RCDTF Recordati Industria Chimica E Farmaceutica	N/A	$0.91	N/A	$0.65	N/A	$810.70 million
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion
5/13/2026	Q1 2026	RCDTF Recordati Industria Chimica E Farmaceutica	N/A	$1.08	N/A	$0.88	N/A	$834.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
OTSKY Otsuka	$0.26	0.67%	N/A	10.44%	N/A
RCDTF Recordati Industria Chimica E Farmaceutica	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A
UCBJY UCB	$0.53	0.42%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OTSKY Otsuka	0.05	2.17	1.67
RCDTF Recordati Industria Chimica E Farmaceutica	0.85	1.26	0.86
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67
UCBJY UCB	0.20	1.38	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OTSKY Otsuka	N/A
RCDTF Recordati Industria Chimica E Farmaceutica	N/A
TEVA Teva Pharmaceutical Industries	54.05%
UCBJY UCB	N/A

Insider Ownership

Company	Insider Ownership
OTSKY Otsuka	N/A
RCDTF Recordati Industria Chimica E Farmaceutica	N/A
TEVA Teva Pharmaceutical Industries	0.54%
UCBJY UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OTSKY Otsuka	37,758	1.07 billion	N/A	Not Optionable
RCDTF Recordati Industria Chimica E Farmaceutica	4,693	206.30 million	N/A	Not Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable
UCBJY UCB	10,117	378.04 million	N/A	Not Optionable

RCDTF, UCBJY, TEVA, and OTSKY Headlines

Recent News About These Companies

UCB (OTCMKTS:UCBJY) Upgraded at Jefferies Financial Group

August 6, 2026 | americanbankingnews.com

UCB ADR (UCBJY) Ratios

July 3, 2026 | uk.investing.com

UCB SA (UCBJY) Analyst/Investor Day Transcript

June 12, 2026 | seekingalpha.com

UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial

May 19, 2026 | msn.com

UCB ADR Stock Price History

May 16, 2026 | investing.com

Belgian pharma UCB to buy US.-based Neurona for up to $1.15B

April 17, 2026 | msn.com

UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know

April 15, 2026 | zacks.com

Belgium's UCB in autoimmune drug deal with Antengene

March 3, 2026 | reuters.com

Berenberg maintains UCB SA - depositary receipt (UCBJY) buy recommendation

December 16, 2025 | msn.com

Recent Price Trend in UCB (UCBJY) is Your Friend, Here's Why

September 25, 2025 | zacks.com

UCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why

September 9, 2025 | zacks.com

All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy

August 22, 2025 | msn.com

Here's Why Momentum in UCB (UCBJY) Should Keep going

August 6, 2025 | msn.com

UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 16, 2025 | msn.com

UCB SA’s Growth Potential: Buy Rating on Bimzelx’s Transformative Impact

July 16, 2025 | tipranks.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price ... - Nasdaq

July 11, 2025 | nasdaq.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price Strength

July 9, 2025 | msn.com

TD Cowen maintains UCB stock Buy rating, EUR250 target

March 27, 2025 | uk.investing.com

UCB SA (UCBJY)

February 2, 2025 | finance.yahoo.com

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

January 17, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCDTF, UCBJY, TEVA, and OTSKY Company Descriptions

Otsuka OTCMKTS:OTSKY

$39.05 +0.39 (+1.00%)

As of 03:55 PM Eastern

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

$58.00 0.00 (0.00%)

As of 08/11/2026

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Teva Pharmaceutical Industries NYSE:TEVA

$36.52 -0.22 (-0.61%)

Closing price 03:59 PM Eastern

Extended Trading

$36.50 -0.02 (-0.05%)

As of 06:05 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

UCB OTCMKTS:UCBJY

$126.17 -1.62 (-1.27%)

As of 03:50 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCDTF, UCBJY, TEVA, and OTSKY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCDTF, UCBJY, TEVA, and OTSKY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCDTF, UCBJY, TEVA, and OTSKY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCDTF, UCBJY, TEVA, and OTSKY Company Descriptions

Otsuka OTCMKTS:OTSKY

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

Teva Pharmaceutical Industries NYSE:TEVA

UCB OTCMKTS:UCBJY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCDTF, UCBJY, TEVA, and OTSKY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCDTF, UCBJY, TEVA, and OTSKY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCDTF, UCBJY, TEVA, and OTSKY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCDTF, UCBJY, TEVA, and OTSKY Company Descriptions

Otsuka OTCMKTS:OTSKY

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

Teva Pharmaceutical Industries NYSE:TEVA

UCB OTCMKTS:UCBJY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools